Abemaciclib and Elacestrant trial opens for brain metastasis in ER+/HER-2- breast cancer
A recruiting Phase 1/Phase 2 study is testing Abemaciclib and Elacestrant in participants with brain metastasis due to ER+/HER-2- breast cancer, with early dose and response goals.
A new ClinicalTrials.gov registry observation says the Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer is now RECRUITING. The posting is dated 2026-11-19T00:00:00+00:00, and the record lists an estimated primary completion date of 2027-08.
For patients and families looking for what this means, the key point is simple: the study is still at the testing stage, so it is about gathering evidence, not reporting a settled result. The record also says has_results is false, which means outcomes are not posted here.
How the study is set up
The trial is Phase 1, Phase 2 and NON_RANDOMIZED, with four arm groups: Phase 1b Cohort 1, Phase 1b Cohort 2, Phase 1b Cohort 3 and Phase 2. Stemline Therapeutics, Inc. is listed as sponsor, and the interventions are Elacestrant and Abemaciclib across the listed cohorts.
In Phase 1b, the primary outcome is RP2D, short for recommended phase 2 dose. The record says that dose will be based on the observed number of dose-limiting toxicities during Cycle 1 (28 days), with toxicity judged using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
What Phase 2 will look for
The Phase 2 primary outcome is Objective Response Rate, or ORR, per RECIST V1.1 over 3 years. In plain terms, the study will look at the share of participants whose best overall response is a confirmed complete response or partial response, as assessed by blinded independent central review.
That makes the study relevant to anyone tracking how researchers are trying to measure whether a treatment does more than tolerate well. It is also a reminder that early cancer studies often have two jobs at once: finding a workable dose and checking whether the treatment shows activity.
Why this registry update stands out now
This registry update sits within the active Cancer Breakthroughs special event, alongside other recent cancer-related study postings. The shared thread is not that the studies answer the same question, but that they show ongoing clinical testing across different cancer settings.
For readers following breast cancer research, this one is notable because it focuses on brain metastasis, a setting that is especially hard to treat. The registry itself does not say how the study will turn out, only that recruitment is underway and the study is still being measured against its planned outcomes.
"This record describes a study and its registry status; study outcomes require posted results."